Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer

Birol OCAK; Süreyya SARIHAN; Ahmet Bilgehan ŞAHİN; Bahar DAKİKİ; Burcu CANER; Kemal GÜLŞEN; Özgür TANRIVERDİ; Adem DELİGÖNÜL; Erdem ÇUBUKÇU; Türkkan EVRENSEL

doi:https://doi.org/10.46310/tjim.1076459

Makale detayları

Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer

Yazarlar:

Birol OCAK | Süreyya SARIHAN | Ahmet Bilgehan ŞAHİN | Bahar DAKİKİ | Burcu CANER | Kemal GÜLŞEN | Özgür TANRIVERDİ | Adem DELİGÖNÜL | Erdem ÇUBUKÇU | Türkkan EVRENSEL

Yayıncı:

Nizameddin KOCA

Ana Başlıklar:

Hastalıklar

Dergi:

Turkish Journal of Internal Medicine 2022 Vol.4, pp.71-80

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000637612

Sıklık:

Üç Aylık

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.1076459

Özet:

 

Background: In non-small cell lung cancer (NSCLC), immunotherapy is a treatment option in patients without targetable mutations in second and later lines. Nevertheless, there is no validated test that can predict immunotherapy response.
Material and Methods: Our study aimed to investigate the effect of radiotherapy (RT) on survival in patients with NSCLC receiving immunotherapy after first-line chemotherapy. Twenty-five patients diagnosed with NSCLC and received immunotherapy after at least one previous chemotherapy line were included in our study.
Results: The median age of the patients was 61.7 (26.6-81.2) years. 19 (76%) patients were male. 11 (44%) of the patients had received immunotherapy in the second-line and 14 (66%) in ≥3 lines. Patients had received a median of 5 cycles (1-27) of immunotherapy. RT to immunotherapy interval was 6.4 months (1.0-11.8). Partial response was observed in 12 patients, stable disease in 8 patients, progression in 1 patient, and hyperprogression in 4 patients. Median progression-free survival (PFS) was 4.4 months (95% CI; 3.2-5.6), and median overall survival (OS) was 16.4 months (95% CI; 5.6-27.3). 14 (56%) of the patients had received RT. RT was administered to 12 patients before immunotherapy, and two patients received RT to bones during immunotherapy. The patients who received RT had statistically longer PFS (4.9 vs 3.9 months, p=0.012) and OS (18.7 vs 7.3 months, p=0.023) comparing those without RT. 
Conclusions: Our findings showed that RT significantly improved the survival in patients who received immunotherapy, pointing that RT may have an influential role in immunotherapy response.

Makale detayları

Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer

Yazarlar: Birol OCAK | Süreyya SARIHAN | Ahmet Bilgehan ŞAHİN | Bahar DAKİKİ | Burcu CANER | Kemal GÜLŞEN | Özgür TANRIVERDİ | Adem DELİGÖNÜL | Erdem ÇUBUKÇU | Türkkan EVRENSEL

Yayıncı: Nizameddin KOCA

Ana Başlıklar: Hastalıklar

Dergi: Turkish Journal of Internal Medicine 2022 Vol.4, pp.71-80

Belge Tipi: Makale

Yayın Tarihi: 3/2022

Belge Dili: İngilizce

Document ID (Org No.): 2000637612

Sıklık: Üç Aylık

eISSN: 2687-4245

DOI: https://doi.org/10.46310/tjim.1076459

Sayı

Yazarlar:

Birol OCAK | Süreyya SARIHAN | Ahmet Bilgehan ŞAHİN | Bahar DAKİKİ | Burcu CANER | Kemal GÜLŞEN | Özgür TANRIVERDİ | Adem DELİGÖNÜL | Erdem ÇUBUKÇU | Türkkan EVRENSEL

Yayıncı:

Nizameddin KOCA

Ana Başlıklar:

Hastalıklar

Dergi:

Turkish Journal of Internal Medicine 2022 Vol.4, pp.71-80

Belge Tipi:

Makale

Yayın Tarihi:

3/2022

Belge Dili:

İngilizce

Document ID (Org No.):

2000637612

Sıklık:

Üç Aylık

eISSN:

2687-4245

DOI:

https://doi.org/10.46310/tjim.1076459